Utrogestan 200mg是什么药

解密安琪坦

在试管婴儿治疗过程中,取卵日开始,很多患者朋友会接触到一种叫安琪坦的药物。安琪坦也叫黄体酮软胶囊,是一种浅黄色不透明的软胶囊,内容物为均匀的白色糊状混悬液。安琪坦是微粉化的天然黄体酮,其结构与人体孕酮完全一致,对母亲和胎儿高度安全,是目前最为常用的黄体支持药物之一。

我该怎么用?

安琪坦有两种用法,分别是阴道给药和口服给药。具体的用药方式和剂量应由医生根据患者的实际情况来决定。

采用阴道是一种安全性高,使用方便的给药方式。软胶囊塞入阴道后,黄体酮会被阴道粘膜迅速吸收,通过子宫首过效应,子宫局部会有较高的孕酮浓度。

不影响内分泌、肝肾功能,也不会产生全身性的副作用。偶然伴有嗜睡和头晕的感觉,是不用紧张的,也不需要做特殊处理。

阴道用药具体方法

阴道塞药前应先清洁双手,将胶囊塞入阴道深处,通常是约一指深度就可以了,避免塞得过浅药丸流出。塞完后无需卧床,完全可以正常活动。由于除孕酮有效成分外,还会有赋形剂成分不能被阴道吸收而积存在阴道内,在使用过程中,常常有药渣间断排出,这不会影响药物的吸收,也不影响药效。

如果偶尔漏用该药物,请您不要紧张,更不要补偿性的加倍使用。一般每次的阴道用药剂量不超过200mg,也就是说每次2粒比较合适。如果您的医生要求您每日用6粒安琪坦,那么您可以分早、中、晚三次使用。

温馨提示

对了,您知道吗?安琪坦中含有花生油的成分,如果您对花生过敏,那么就容易对安琪坦过敏,请及时告知医生哟。

常见问题汇总

1、用了阴道黄体酮制剂如安琪坦塞药后流出来怎么办?

阴道用安琪坦后,会流出白色液体。这是正常的,不会影响药物的作用,药物在制剂过程中,需要通过辅料将药物成份制成栓剂或者片剂等有形制剂。药物被上进阴道后,通过阴道粘膜吸收了有效成份,剩余的药物残渣多是淀粉,最后排出来,是药物吸收的表现。

2、请问阴道安琪坦用药后白色药渣比较多,怎么清理?可以每天早晚用盆洗洗吗?

阴道用药后,赋形剂(即药物辅料)会自阴道内排出,不会影响药效,也无需特殊清理,正常淋浴即可。

3、安琪坦有什么缺点吗?

缺点:用药次数频繁,阴道用药易引起外阴瘙痒,阴道炎;直肠给药可能造成痔疮出血,刺激直肠引起腹泻。

4、冻胚移植十二天,刚刚出了点鲜血,好像跟上次生化差不多。现在早晚吃达芙通,还有塞的安琪坦,现在出血了,晚上安琪坦还需要塞吗?

如果出血不多可以继续使用安琪坦的,不要随便停药。

2. Demko ZP, Simon AL, McCoy RC, et al. Effects of maternal age on euploidy rates in a large cohort of embryos analyzed with 24-chromosome single-nucleotide polymorphism-based preimplantation genetic screening. Fertil Steril. 2016;105(5):1307–13. doi: 10.1016/j.fertnstert.2016.01.025.
[Demko ZP, Simon AL, McCoy RC, et al. Effects of maternal age on euploidy rates in a large cohort of embryos analyzed with 24-chromosome single-nucleotide polymorphism-based preimplantation genetic screening[J]. Fertil Steril, 2016, 105(5): 1307-13.] [PubMed] [CrossRef] [Google Scholar]

3. Dang TT, Phung TM, Le H, et al. Preimplantation genetic testing of aneuploidy by next generation sequencing: association of maternal age and chromosomal abnormalities of blastocyst. Open Access Maced J Med Sci. 2019;7(24):4427–31. doi: 10.3889/oamjms.2019.875.
[Dang TT, Phung TM, Le H, et al. Preimplantation genetic testing of aneuploidy by next generation sequencing: association of maternal age and chromosomal abnormalities of blastocyst[J]. Open Access Maced J Med Sci, 2019, 7(24): 4427-31.] [PMC free article] [PubMed] [CrossRef] [Google Scholar]

4. 王 晓丽, 王 培红, 钱 红丽. 三种黄体支持方案对IVF/ICSI临床结局的影响 生殖医学杂志 2019;28(12):1410–5. doi: 10.3969/j.issn.1004-3845.2019.12.004.
[王晓丽, 王培红, 钱红丽. 三种黄体支持方案对IVF/ICSI临床结局的影响[J]. 生殖医学杂志, 2019, 28(12): 1410-5.] [CrossRef] [Google Scholar]

5. 孙 青苗, 金 彦, 陈 捷, et al. 肌肉注射黄体酮致局部不良反应相关因素分析 中国药物应用与监测 2009;6(5):300–2. doi: 10.3969/j.issn.1672-8157.2009.05.011.
[孙青苗, 金彦, 陈捷, 等. 肌肉注射黄体酮致局部不良反应相关因素分析[J]. 中国药物应用与监测, 2009, 6(5): 300-2.] [CrossRef] [Google Scholar]

6. Bulletti C, de Ziegler D, Flamigni C, et al. Targeted drug delivery in gynaecology: the first uterine pass effect. Hum Reprod. 1997;12(5):1073–9. doi: 10.1093/humrep/12.5.1073.
[Bulletti C, de Ziegler D, Flamigni C, et al. Targeted drug delivery in gynaecology: the first uterine pass effect[J]. Hum Reprod, 1997, 12 (5): 1073-9.] [PubMed] [CrossRef] [Google Scholar]

7. Beltsos AN, Sanchez MD, Doody KJ, et al. Patients' administration preferences: progesterone vaginal insert (Endometrin®) compared to intramuscular progesterone for Luteal phase support. Reprod Health. 2014;11:78–83. doi: 10.1186/1742-4755-11-78.
[Beltsos AN, Sanchez MD, Doody KJ, et al. Patients' administration preferences: progesterone vaginal insert (Endometrin®) compared to intramuscular progesterone for Luteal phase support[J]. Reprod Health, 2014, 11: 78-83.] [PMC free article] [PubMed] [CrossRef] [Google Scholar]

8. Chi H, Li R, Qiao J, et al. Vaginal progesterone gel is non-inferior to intramuscular progesterone in efficacy with acceptable tolerability for luteal phase support: a prospective, randomized, multicenter study in China. Eur J Obstet Gynecol Reprod Biol. 2019;237:100–5. doi: 10.1016/j.ejogrb.2019.04.012.
[Chi H, Li R, Qiao J, et al. Vaginal progesterone gel is non-inferior to intramuscular progesterone in efficacy with acceptable tolerability for luteal phase support: a prospective, randomized, multicenter study in China[J]. Eur J Obstet Gynecol Reprod Biol, 2019, 237: 100-5.] [PubMed] [CrossRef] [Google Scholar]

10. Levy T, Yairi Y, Bar-Hava I, et al. Pharmacokinetics of the progesterone-containing vaginal tablet and its use in assisted reproduction. http://www.sciencedirect.com/science/article/pii/S0039128X00001215. Steroids. 2000;65(10/11):645–9.
[Levy T, Yairi Y, Bar-Hava I, et al. Pharmacokinetics of the progesterone-containing vaginal tablet and its use in assisted reproduction[J]. Steroids, 2000, 65(10/11): 645-9.] [PubMed] [Google Scholar]

11. 翟 国敏, 高 宇琳, 黄 健初, et al. 不同阴道给药黄体支持方案对激素替代治疗周期冻融胚胎移植患者妊娠结局的影响 中国当代医药 2020;27(5):112–4. doi: 10.3969/j.issn.1674-4721.2020.05.034.
[翟国敏, 高宇琳, 黄健初, 等. 不同阴道给药黄体支持方案对激素替代治疗周期冻融胚胎移植患者妊娠结局的影响[J]. 中国当代医药, 2020, 27(5): 112-4.] [CrossRef] [Google Scholar]

12. Wang LJ, Huang FJ, Kung FT, et al. Comparison of the efficacy of two vaginal progesterone formulations, Crinone 8% gel and Utrogestan capsules, used for luteal support in blastocyst stage embryo transfers. Taiwan J Obstet Gynecol. 2009;48(4):375–9. doi: 10.1016/S1028-4559(09)60326-0.
[Wang LJ, Huang FJ, Kung FT, et al. Comparison of the efficacy of two vaginal progesterone formulations, Crinone 8% gel and Utrogestan capsules, used for luteal support in blastocyst stage embryo transfers[J]. Taiwan J Obstet Gynecol, 2009, 48(4): 375-9.] [PubMed] [CrossRef] [Google Scholar]

13. 张 少娣, 李 秋圆, 张 翠莲. 两种不同阴道给药黄体支持方案用于激素替代FET周期的临床结局比较 生殖医学杂志 2019;28(1):18–22. doi: 10.3969/j.issn.1004-3845.2019.01.004.
[张少娣, 李秋圆, 张翠莲. 两种不同阴道给药黄体支持方案用于激素替代FET周期的临床结局比较[J]. 生殖医学杂志, 2019, 28(1): 18-22.] [CrossRef] [Google Scholar]

14. Tomic V, Tomic J, Klaic DZ. Oral micronized progesterone combined with vaginal progesterone gel for luteal support. Gynecol Endocrinol. 2011;27(12):1010–3. doi: 10.3109/09513590.2011.569791.
[Tomic V, Tomic J, Klaic DZ. Oral micronized progesterone combined with vaginal progesterone gel for luteal support[J]. Gynecol Endocrinol, 2011, 27(12): 1010-3.] [PubMed] [CrossRef] [Google Scholar]

15. Shiba R, Kinutani M, Okano S, et al. Efficacy of four vaginal progesterones for luteal phase support in frozen-thawed embryo transfer cycles: a randomized clinical trial. Reprod Med Biol. 2020;19(1):42–9. doi: 10.1002/rmb2.12300.
[Shiba R, Kinutani M, Okano S, et al. Efficacy of four vaginal progesterones for luteal phase support in frozen-thawed embryo transfer cycles: a randomized clinical trial[J]. Reprod Med Biol, 2020, 19(1): 42-9.] [PMC free article] [PubMed] [CrossRef] [Google Scholar]

16. Child T, Leonard SA, Evans JS, et al. Systematic review of the clinical efficacy of vaginal progesterone for luteal phase support in assisted reproductive technology cycles. Reprod Biomed Online. 2018;36(6):630–45. doi: 10.1016/j.rbmo.2018.02.001.
[Child T, Leonard SA, Evans JS, et al. Systematic review of the clinical efficacy of vaginal progesterone for luteal phase support in assisted reproductive technology cycles[J]. Reprod Biomed Online, 2018, 36(6): 630-45.] [PubMed] [CrossRef] [Google Scholar]

17. Michnova L, Dostal J, Kudela M, et al. Vaginal use of micronized progesterone for luteal support. A randomized study comparing Utrogestan® and Crinone® 8. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2017;161(1):86–91. doi: 10.5507/bp.2017.007.
[Michnova L, Dostal J, Kudela M, et al. Vaginal use of micronized progesterone for luteal support. A randomized study comparing Utrogestan® and Crinone® 8[J]. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub, 2017, 161(1): 86-91.] [PubMed] [CrossRef] [Google Scholar]

18. Michnová L, Dostál J, Langová K, et al. Comparison of vaginal use of micronized progesterone for the luteal support. Randomized study comparison of utrogestan and crinone 8. http://www.ncbi.nlm.nih.gov/pubmed/28252308. Ceska Gynekol. 2017;82(1):28–37.
[Michnová L, Dostál J, Langová K, et al. Comparison of vaginal use of micronized progesterone for the luteal support. Randomized study comparison of utrogestan and crinone 8[J]. Ceska Gynekol, 2017, 82(1): 28-37.] [PubMed] [Google Scholar]

19. 汪 卫军, 董 英杰, 金 一. 黄体酮阴道缓释凝胶的制备及质量控制方法的研究 中国药学杂志 2008;43(17):1322–6. doi: 10.3321/j.issn:1001-2494.2008.17.010.
[汪卫军, 董英杰, 金一. 黄体酮阴道缓释凝胶的制备及质量控制方法的研究[J]. 中国药学杂志, 2008, 43(17): 1322-6.] [CrossRef] [Google Scholar]

20. Jobanputra K, Toner JP, Denoncourt R, et al. Crinone 8% (90 mg) given once daily for progesterone replacement therapy in donor egg cycles. Fertil Steril. 1999;72(6):980–4. doi: 10.1016/S0015-0282(99)00390-8.
[Jobanputra K, Toner JP, Denoncourt R, et al. Crinone 8% (90 mg) given once daily for progesterone replacement therapy in donor egg cycles[J]. Fertil Steril, 1999, 72(6): 980-4.] [PubMed] [CrossRef] [Google Scholar]

21. 许 科, 陈 莉, 陈 洋, et al. 黄体酮阴道缓释凝胶在FET周期不同内膜准备方案中黄体支持的效果分析 生殖医学杂志 2018;27(3):232–6. doi: 10.3969/j.issn.1004-3845.2018.03.008.
[许科, 陈莉, 陈洋, 等. 黄体酮阴道缓释凝胶在FET周期不同内膜准备方案中黄体支持的效果分析[J]. 生殖医学杂志, 2018, 27(3): 232-6.] [CrossRef] [Google Scholar]